SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer

Key Points

• To compare long-term outcomes of SBRT and HDR brachytherapy for treating intermediate-risk prostate cancer.
• Post hoc pooled analysis
• Used prospective data
• Compared biochemical control failure and acute genitourinary adverse events
• SBRT resulted in significantly lower biochemical control failure (BCF) rates.
• SBRT had significantly fewer acute genitourinary adverse events (AEs).
• No significant difference in late patient-reported quality of life (PR-QoL) between the two treatments.